{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0062374\nAge: 66\nGender: Male\nSample ID: P-0062374-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Pancreatic Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 20.0%\n=============\nDNA Variants:\nBRAF c.1799_1801del (p.V600_K601delinsE) - in 15.00% of 137 reads\nCDKN2A c.151-2_152delinsC (p.X51_splice) - in 25.00% of 357 reads\nFOXL2 c.655C>T (p.Q219*) - in 8.00% of 225 reads\nSMAD4 c.355T>A (p.F119I) - in 10.00% of 153 reads\nTP53 c.817C>T (p.R273C) - in 16.00% of 384 reads\nTSC2 c.3308G>C (p.R1103T) - in 9.00% of 411 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}